Scroll

propranolol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
beta-adrenoreceptor antagonists	2303	525-66-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: propranolol betalong DL-Propranolol racemic propranolol beta-Propranolol propranolol hydrochloride hemangiol propranolol HCl	A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Molecular weight: 259.35 Formula: C16H21NO2 CLOGP: 2.75 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 41.49 ALOGS: -3.51 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

propranolol
betalong
DL-Propranolol
racemic propranolol
beta-Propranolol
propranolol hydrochloride
hemangiol
propranolol HCl

A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.

Molecular weight: 259.35
Formula: C16H21NO2
CLOGP: 2.75
LIPINSKI: 0
HAC: 3
HDO: 2
TPSA: 41.49
ALOGS: -3.51
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.16	g	O
0.16	g	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
S (Water solubility)	50 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	35.25 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
t_half (Half-life)	3.40 hours	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	3.10 L/kg	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	26 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
CL (Clearance)	12 mL/min/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.25 %	Benet LZ, Broccatelli F, Oprea TI
fu (Fraction unbound in plasma)	0.13 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Nov. 13, 1967	FDA	BAXTER HLTHCARE CORP

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product administered to patient of inappropriate age	1151.63	10.08	333	75639	2935	63410115
Completed suicide	788.43	10.08	920	75052	144753	63268297
Toxicity to various agents	409.66	10.08	909	75063	246341	63166709
Bradycardia	397.97	10.08	464	75508	72763	63340287
Drug ineffective for unapproved indication	376.55	10.08	318	75654	33745	63379305
Off label use	351.99	10.08	1664	74308	672798	62740252
Cardiac arrest	286.82	10.08	446	75526	92099	63320951
Infantile spitting up	232.75	10.08	46	75926	44	63413006
Coma	201.86	10.08	312	75660	64052	63348998
Overdose	195.62	10.08	428	75544	114650	63298400

Showing 1 to 10 of 363 entries

Previous1 2 3 4 5…37Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product administered to patient of inappropriate age	525.90	11.06	182	40285	3109	34913355
Completed suicide	299.70	11.06	461	40006	97707	34818757
Bradycardia	264.31	11.06	378	40089	75040	34841424
Toxicity to various agents	177.70	11.06	572	39895	199790	34716674
Hepatic encephalopathy	176.61	11.06	142	40325	14543	34901921
Product use issue	172.13	11.06	282	40185	62934	34853530
Product use in unapproved indication	135.96	11.06	369	40098	117130	34799334
Intentional overdose	108.38	11.06	187	40280	43487	34872977
Nightmare	105.06	11.06	105	40362	14286	34902178
Cardiac arrest	92.74	11.06	283	40184	95876	34820588

Showing 1 to 10 of 210 entries

Previous1 2 3 4 5…21Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	1128.96	10.07	1418	92711	244349	79405910
Bradycardia	584.51	10.07	759	93370	134798	79515461
Product administered to patient of inappropriate age	570.32	10.07	223	93906	5330	79644929
Toxicity to various agents	518.19	10.07	1369	92760	420171	79230088
Cardiac arrest	388.02	10.07	714	93415	171382	79478877
Drug ineffective for unapproved indication	350.29	10.07	364	93765	50874	79599385
Intentional overdose	317.29	10.07	499	93630	105461	79544798
Overdose	231.33	10.07	604	93525	183602	79466657
Product use in unapproved indication	229.41	10.07	733	93396	249626	79400633
Hepatic encephalopathy	210.43	10.07	196	93933	23970	79626289

Showing 1 to 10 of 432 entries

Previous1 2 3 4 5…44Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	C07AA05	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Beta blocking agents, non-selective
ATC	C07BA05	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND THIAZIDES Beta blocking agents, non-selective, and thiazides
ATC	C07FX01	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS, OTHER COMBINATIONS Beta blocking agents, other combinations
CHEBI has role	CHEBI:35474	anti-anxiety agents
CHEBI has role	CHEBI:35530	beta-adrenergic blockers
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:38070	antiarrhythmic agent
CHEBI has role	CHEBI:78298	environmental contaminants

Showing 1 to 10 of 21 entries

Previous1 2 3Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Supraventricular tachycardia	indication	6456007
Hypertensive disorder	indication	38341003	DOID:10763
Atrial fibrillation	indication	49436004	DOID:0060224
Angina pectoris	indication	194828000
Hypertrophic cardiomyopathy	indication	233873004	DOID:11984
Idiopathic hypertrophic subaortic stenosis	indication	360465008
Hemangioma	indication	400210000	DOID:255
Essential tremor	indication	609558009	DOID:4990
Life-Threatening Ventricular Tachycardia	indication
Ulcerated haemangioma	indication

Showing 1 to 10 of 62 entries

Previous1 2 3 4 5 6 7Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.19	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
4.28MG/ML	HEMANGEOL	PIERRE FABRE DERMA	N205410	March 14, 2014	RX	SOLUTION	ORAL	8338489	Oct. 16, 2028	METHOD TO TREAT HEMANGIOMA.
4.28MG/ML	HEMANGEOL	PIERRE FABRE DERMA	N205410	March 14, 2014	RX	SOLUTION	ORAL	8987262	Oct. 16, 2028	METHOD TO TREAT INFANTILE HEMANGIOMA

Showing 1 to 2 of 2 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	ANTAGONIST	Ki	8.71	WOMBAT-PK	DRUG LABEL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	ANTAGONIST	Ki	8.25	WOMBAT-PK	DRUG LABEL
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		Ki	4.32	CHEMBL
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	6.70	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.91	PDSP
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	5.38	PDSP
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	6.66	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	5.92	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	5.85	DRUG MATRIX
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	4.70	WOMBAT-PK

Showing 1 to 10 of 32 entries

Previous1 2 3 4Next

External reference:

Show entries

Search:

ID	Source
001850	NDDF
004740	NDDF
1940	INN_ID
2240	MMSL
318-98-9	SECONDARY_CAS_RN
372772003	SNOMEDCT_US
4017831	VANDF
4019916	VUID
4019916	VANDF
4946	PUBCHEM_CID

Showing 1 to 10 of 25 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Propranolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-3727	SOLUTION	20 mg	ORAL	ANDA	11 sections
Propranolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-3727	SOLUTION	20 mg	ORAL	ANDA	11 sections
Propranolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-3730	SOLUTION	40 mg	ORAL	ANDA	11 sections
Propranolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-3730	SOLUTION	40 mg	ORAL	ANDA	11 sections
Propranolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1659	TABLET	10 mg	ORAL	ANDA	21 sections
Propranolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1660	TABLET	20 mg	ORAL	ANDA	21 sections
Propranolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1661	TABLET	40 mg	ORAL	ANDA	21 sections
Propranolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1662	TABLET	80 mg	ORAL	ANDA	21 sections
Propranolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1693	TABLET	60 mg	ORAL	ANDA	19 sections
Propranolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0908	SOLUTION	20 mg	ORAL	ANDA	11 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next